CRISPRおよびCas遺伝子の市場規模、シェア、動向分析レポート：エンドユーザー別（CRO、バイオテクノロジーおよび製薬会社）、用途別（バイオメディカル、農業）、製品・サービス別、地域別、セグメント別予測、2022年～2030年

CRISPRおよびCas遺伝子の市場成長と動向

Grand View Research, Inc.の新しいレポートによると、世界のCRISPRおよびCas遺伝子市場規模は、2030年までに96億米ドルに達すると予測されています。この市場は、生物医学研究分野におけるCRISPRおよびCas遺伝子システムの利用が増加していることから、予測期間中に17.9%のCAGRを記録すると予想されています。ゲノム編集分野の発展により、原核生物における診断や進化解析の評価におけるCRISPR-Casシステムの利用が大幅に増加しています。この技術の応用により、簡単かつ低コストで遺伝子を編集することが可能になりました。ゲノム編集は生物医学研究を大きく前進させ、現在の最先端技術の動向は、さまざまな遺伝性および非遺伝性疾患の将来の治療への道を開くものです。

CRISPR/Cas9を介した遺伝子およびゲノム編集技術の利用により、遺伝子ターゲティングのより効果的な方法の開発と実施、および遺伝子編集鳥類の作出が促進されました。2021年2月にFrontiersに掲載された論文によると、CRISPR/Cas9は家禽産業における遺伝子編集のための強固で重要なツールとなっています。いくつかの分野での応用の可能性が、この技術の需要をさらに押し上げると思われます。COVID-19の発生は、研究者の重点をこの技術に基づくCOVID-19分子診断ツールの開発にシフトさせた。例えば、2021年3月、シンガポールの南洋理工大学の研究者は、30分で結果が出るCRISPRに基づくCOVID-19検査を作成しました。

ウイルスが変異した後でも、このテストはそれを発見します。これは、他の主要なプレーヤーがこの技術を活用することをさらに促し、それによって業界の成長を促進することになるでしょう。この技術は、医療やその他の用途にますます利用されるようになってきています。このような遺伝子編集技術の特許をめぐる競争は、この技術の新たな商業的応用を開発しようとする学術機関やバイオテクノロジー企業の増加によって、ますます激しくなると予想されます。また、この技術は、機械学習技術の活用により、さらに進化する可能性を秘めています。例えば、2022年8月、Synthego社は、機能スクリーニング実験に直接使用できるようにCRISPRを編集した細胞を配列したものを提供し、CRISPRへのアクセスを拡大する最先端のサービス「engineered cell libraries」を開始しました。

疾患研究への応用が期待されます。主要プレイヤーは、遺伝子編集ワークフローの各ステップに対してツールやソリューションを提供しています。複数のツール、サービス、改善されたプロセスを統合することで、迅速かつ少ない労力で研究実験を完了させることが可能になります。さらに、主要プレイヤーは、CRISPR &Cas9遺伝子編集アプローチの研究開発を支援するために多額の資金を調達しています。例えば、2021年4月、Vertex PharmaceuticalsはCRISPR Therapeuticsと共同で、輸血依存性βサラセミアおよび鎌状赤血球症（SCD）の治療オプションとなり得る、CTX001というCRISPR/Cas9ベースの新しい遺伝子編集療法を開発・製造することを発表しました。2020年1月、マンモスバイオサイエンスは、治療・診断目的の次世代CRISPR製品の開発に向けて4500万米ドルを調達しました。これはさらに、同社のCRISPR遺伝子駆動診断ポートフォリオを開発するために使用されるでしょう。

CRISPRおよびCas遺伝子市場レポートハイライト

製品およびサービス別では、幅広い製品ポートフォリオの利用可能性と様々なエンドユーザーによる採用の増加により、製品セグメントが2021年に業界を支配しました。

バイオメディカルセグメントが2021年の業界を支配。ゲノム編集のための高度な技術を利用した広範な研究と研究数の大幅な増加がセグメント成長に寄与している

バイオテクノロジー＆製薬企業のエンドユーズセグメントは、2021年に主要な収益シェアを獲得しました。主要プレイヤーは、ヒト疾患の生物学的モデルを作成し、新しい治療標的の特定をさらに加速させるためにこの技術を採用している

北米は、複数の製薬大手の存在、研究資金の増加、研究承認の多さ、新規治療薬の必要性などから、2021年に最も高い売上高シェアを獲得しました。

目次

第1章 調査手法と範囲

• 市場セグメンテーションと範囲
  • 地域範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析（モデル1）
    • アプローチ1：コモディティフローアプローチ
• 調査の仮定
• 市場シェアの計算
• 二次情報のリスト
• 略語一覧
• 目的

第2章 エグゼクティブサマリー

• 市場概要

第3章 CRISPRおよびCas遺伝子市場の変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場促進要因分析
  • 新しい治療法に対するニーズの高まり
  • 遺伝子編集の需要の高まり
  • がんの発生率の上昇
• 市場抑制要因分析
  • Crisprテクノロジーのオフターゲット効果
  • 高コスト要因、知的財産紛争、倫理的ジレンマ
• Crispr &Cas Genes市場-Swot分析、要因別（政治と法律、経済と技術）
• 業界分析- ポーターズ

第4章 製品とサービスのビジネス分析

• CRISPRおよびCas遺伝子市場：製品およびサービスの変動分析
  • 製品別
    • キットと酵素
    • ベクターベースのCas9
    • DNAフリーのCas9
    • ライブラリ
    • 設計ツール
    • 抗体
    • その他
  • サービス別
    • 細胞株工学
    • gRNAの設計
    • 微生物遺伝子編集
    • DNA合成

第5章 アプリケーションビジネス分析

• CRISPRおよびCas遺伝子市場：アプリケーションの変動分析
  • 生物医学
    • ゲノム工学
    • 疾患モデル研究
    • 機能ゲノミクス
    • エピジェネティクス
    • その他
  • 農業

第6章 最終用途のビジネス分析

• CRISPRおよびCas遺伝子市場：最終用途の変動分析
  • バイオテクノロジーおよび製薬会社
  • 学術機関および政府調査機関
  • 受託調査機関（Cros）

第7章 市場の分類：製品、アプリケーション、最終用途別の地域推定・動向分析

• 地域市場のスナップショット
• SWOT分析、要因別（政治と法律、経済と技術）
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東とアフリカ
• 市場規模、予測、トレンド分析、2021年から2030年
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
• アジア太平洋地域
  • 日本
  • 中国
  • 韓国
  • インド
• ラテンアメリカ
  • ブラジル
  • メキシコ
• 中東およびアフリカ（Mea）
  • 南アフリカ
  • サウジアラビア

第8章 競合情勢

• Top CRISPR イノベーター and Their Research Focus
• 戦略的枠組み
• 市場参入企業の分類
• 企業プロファイル
  • CARIBOU BIOSCIENCES
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • ASTRAZENECA
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • INTELLIA THERAPEUTICS, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • ADDGENE
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
  • CRISPR THERAPEUTICS
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • NEW ENGLAND BIOLABS
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • THERMO FISHER SCIENTIFIC, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • SYNTHEGO
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • MAMMOTH BIOSCIENCES
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • INSCRIPTA, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • CIBUS
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • BEAM THERAPEUTICS
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • PLANTEDIT
    • 会社概要
    • 製品のベンチマーク
  • VERTEX PHARMACEUTICALS INCORPORATED
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • GENSCRIPT
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • INTEGRATED DNA TECHNOLOGIES
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • LONZA
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • MERCK
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • HERA BIOLABS
    • 会社概要
    • 製品のベンチマーク
    • 戦略的イニシアチブ
  • ORIGENE TECHNOLOGIES, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
  • RECOMBINETICS, INC.
    • 会社概要
    • 財務実績
    • 製品のベンチマーク
    • 戦略的イニシアチブ

List of Tables

• Table 1 List of Tables
• Table 2 List of Secondary Sources
• Table 3 List of Abbreviations
• Table 4 Global CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 5 Global CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 6 Global CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 7 Global CRISPR and Cas Genes Market, by Region, 2018 - 2030 (USD Million)
• Table 8 North America CRISPR and Cas Genes Market, by Country, 2018 - 2030 (USD Million)
• Table 9 North America CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 10 North America CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 11 North America CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 12 U.S. CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 13 U.S. CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 14 U.S. CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 15 Canada CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 16 Canada CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 17 Canada CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 18 Europe CRISPR and Cas Genes Market, by Country, 2018 - 2030 (USD Million)
• Table 19 Europe CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 20 Europe CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 21 Europe CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 22 Germany CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 23 Germany CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 24 Germany CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 25 U.K. CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 26 U.K. CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 27 U.K. CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 28 France CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 29 France CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 30 France CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 31 Italy CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 32 Italy CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 33 Italy CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 34 Spain CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 35 Spain CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 36 Spain CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 37 Asia Pacific CRISPR and Cas Genes Market, by Country, 2018 - 2030 (USD Million)
• Table 38 Asia Pacific CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 39 Asia Pacific CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 41 China CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 42 China CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 43 China CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 44 Japan CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 45 Japan CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 46 Japan CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 47 India CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 48 India CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 49 India CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 50 South Korea CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 51 South Korea CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 52 South Korea CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 53 Latin America CRISPR and Cas Genes Market, by Country, 2018 - 2030 (USD Million)
• Table 54 Latin America CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 55 Latin America CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 56 Latin America CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 57 Brazil CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 58 Brazil CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 59 Brazil CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 60 Mexico CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 61 Mexico CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 62 Mexico CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 63 Argentina CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 64 Argentina CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 65 Argentina CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 66 Middle East and Africa CRISPR and Cas Genes Market, by Country, 2018 - 2030 (USD Million)
• Table 67 Middle East and Africa CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 68 Middle East and Africa CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 69 Middle East and Africa CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 70 South Africa CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 71 South Africa CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 72 South Africa CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)
• Table 73 Saudi Arabia CRISPR and Cas Genes Market, by Product and Service, 2018 - 2030 (USD Million)
• Table 74 Saudi Arabia CRISPR and Cas Genes Market, by Application, 2018 - 2030 (USD Million)
• Table 75 Saudi Arabia CRISPR and Cas Genes Market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 CRISPR and Cas genes, Market Segmentation
• Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
• Fig. 10 Penetration & Growth Prospect Mapping
• Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 12 Porter's Five Forces Analysis
• Fig. 13 Market Penetration Vs Growth Prospect Mapping, 2021
• Fig. 14 Regional Marketplace: Key Takeaways
• Fig. 15 Global CRISPR and Cas genes Market, for Product, 2018 - 2030 (USD Million)
• Fig. 16 Global CRISPR and Cas genes Market, for Kits & Enzymes, 2018 - 2030 (USD Million)
• Fig. 17 Global CRISPR and Cas genes Market, for Vector-based Cas9 2018 - 2030 (USD Million)
• Fig. 18 Global CRISPR and Cas genes Market, for DNA-free Cas9 2018 - 2030 (USD Million)
• Fig. 19 Global CRISPR and Cas genes Market, for Libraries, 2018 - 2030 (USD Million)
• Fig. 20 Global CRISPR and Cas genes Market, for Design Tool, 2018 - 2030 (USD Million)
• Fig. 21 Global CRISPR and Cas genes Market, for Antibodies , 2018 - 2030 (USD Million)
• Fig. 22 Global CRISPR and Cas genes Market, for Others , 2018 - 2030 (USD Million)
• Fig. 23 Global CRISPR and Cas genes Market, for Service, 2018 - 2030 (USD Million)
• Fig. 24 Global CRISPR and Cas genes Market, for Cell Line Engineering , 2018 - 2030 (USD Million)
• Fig. 25 Global CRISPR and Cas genes Market, for gRNA Design , 2018 - 2030 (USD Million)
• Fig. 26 Global CRISPR and Cas genes Market, for Microbial Gene Editing , 2018 - 2030 (USD Million)
• Fig. 27 Global CRISPR and Cas genes Market, for DNA synthesis , 2018 - 2030 (USD Million)
• Fig. 28 Global CRISPR and Cas genes Market, for Biomedical , 2018 - 2030 (USD Million)
• Fig. 29 Global CRISPR and Cas genes Market, for Genome Engineering, 2018 - 2030 (USD Million)
• Fig. 30 Global CRISPR and Cas genes Market, for Disease Model Studies, 2018 - 2030 (USD Million)
• Fig. 31 Global CRISPR and Cas genes Market, for Functional Genomics , 2018 - 2030 (USD Million)
• Fig. 32 Global CRISPR and Cas genes Market, for Epigenetics, 2018 - 2030 (USD Million)
• Fig. 33 Global CRISPR and Cas genes Market, for Others , 2018 - 2030 (USD Million)
• Fig. 34 Global CRISPR and Cas genes Market, for Agricultural , 2018 - 2030 (USD Million)
• Fig. 35 Global CRISPR and Cas genes Market, for Biotechnology & Pharmaceutical Companies, 2018 - 2030 (USD Million)
• Fig. 36 Global CRISPR and Cas genes Market, for Academics & Government Research Institutes, 2018 - 2030 (USD Million)
• Fig. 37 Global CRISPR and Cas genes Market, for Contract Research Organizations (CROs), 2018 - 2030 (USD Million)
• Fig. 38 Regional Outlook, 2021 & 2030
• Fig. 39 North America CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 40 U.S. CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 41 Canada CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 42 Europe CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 43 Germany CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 44 U.K. CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 45 France CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 46 Italy CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 47 Spain CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 48 Asia Pacific CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 49 Japan CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 50 China CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 51 India CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 52 Latin America CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 53 Brazil CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 54 Mexico CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 55 Middle East and Africa CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 56 South Africa CRISPR and Cas genes Market, 2018 - 2030 (USD Million)
• Fig. 57 Saudi Arabia CRISPR and Cas genes Market, 2018 - 2030 (USD Million)

CRISPR And Cas Genes Market Growth & Trends:

The global CRISPR and Cas genes market size is expected to reach USD 9.6 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 17.9% during the forecast period, owing to the increasing usage of CRISPR and Cas genes systems in the biomedical research field. The use of CRISPR-Cas systems in diagnostics and the assessment of evolutionary analysis in prokaryotes has significantly increased, owing to the developments in the field of genome editing. The application of this technology enables easy and cost-efficient editing of genes. Genome editing has made a significant advancement in biomedical research, with the present trend of cutting-edge techniques paving the way for the future treatment of different genetic and non-genetic disorders.

The development and implementation of more effective ways for gene targeting and the generation of gene-edited avian species have been facilitated by the availability of the CRISPR/Cas9-mediated gene and genome editing technology. According to an article published on Frontiers in February 2021, CRISPR/Cas9 has become a robust and important tool for gene editing in the poultry industry. Potential applications in several fields would further boost the demand for this technology. The COVID-19 outbreak shifted the researcher's emphasis to the development of COVID-19 molecular diagnostic tools based on this technology. For instance, in March 2021, Nanyang Technological University researchers in Singapore created a COVID-19 test based on CRISPR that provides results in 30 minutes.

Even after the virus has mutated, this test still discovers it. This would further encourage the other key players to leverage this technique, thereby driving the industry's growth. This technology is increasingly being used for several medical and other applications. Competition over patents for such a gene-editing technology is expected to grow, as more academic institutions and biotech companies attempt to develop new commercial applications of this technology. In addition, there is a lot of potential for this technique to advance with the use of machine learning technologies. For instance, in August 2022, Synthego launched engineered cell libraries, a cutting-edge service that expands access to CRISPR by giving arrayed CRISPR-edited cells for use directly in functional screening experiments.

It has potential applications in disease research. Key players offer tools and solutions for each step of the gene editing workflow. Integrating several tools, services, and improved processes makes it possible to complete research experiments rapidly and with little effort. Moreover, key players have raised significant funding to support the R&D of the CRISPR & Cas9 gene-editing approach. For instance, in April 2021, Vertex Pharmaceuticals collaborated with CRISPR Therapeutics to develop and manufacture a new CRISPR/Cas9-based gene editing therapy called CTX001, a potential therapeutic option for transfusion-dependent beta-thalassemia and Sickle Cell Disease (SCD). In January 2020, Mammoth Biosciences raised USD 45 million to develop next-gen CRISPR products for therapeutics & diagnostics purposes. This would further be used to develop the company's CRISPR genes-driven diagnostics portfolio.

CRISPR And Cas Genes Market Report Highlights:

• By product and services, the product segment dominated the industry in 2021 due to the availability of a broad range of product portfolios & rising adoption by various end-users

• The biomedical segment dominated the industry in 2021. Extensive research and a significant rise in the number of research studies utilizing the advanced technique for genome editing have contributed to the segment growth

• The biotechnology & pharmaceutical companies end-use segment captured the major revenue share in 2021. Key players are adopting this technology to produce biological models for human diseases and further accelerate new therapeutic target identification

• North America captured the highest revenue share in 2021 owing to the presence of several pharmaceutical giants, increased research funding, a high number of research approvals, and the need for novel therapeutics

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Regional Scope
  • 1.1.2 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity Flow Approach
• 1.7 Research Assumptions
• 1.8 Market Share Calculations
• 1.9 List Of Secondary Sources
• 1.10 List Of Abbreviations
• 1.11 Objectives
  • 1.11.1 Objective 1
  • 1.11.2 Objective 2
  • 1.11.3 Objective 3
  • 1.11.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Summary

Chapter 3 Crispr & Cas Genes Market Variables, Trends And Scope

• 3.1 Market Segmentation & Scope
• 3.2 Market Driver Analysis
  • 3.2.1 Growing Need For Novel Therapeutics
  • 3.2.2 Rising Demand For Gene Editing
  • 3.3.3 Rising Incidence Of Cancer
• 3.3 Market Restraint Analysis
  • 3.3.1 Off-Target Effects Of Crispr Technology
  • 3.3.2 High-Cost Factor, Intellectual Property Disputes & Ethical Dilemma
• 3.4 Crispr & Cas Genes Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
• 3.5 Industry Analysis - Porter's

Chapter 4 Product & Service Business Analysis

• 4.1 Crispr And Cas Genes Market: Product & Service Movement Analysis
  • 4.1.1 By Product
    • 4.1.1.1 Global Crispr And Cas Genes Products Market, 2018 - 2030 (USD Million)
    • 4.1.1.2 Kits & Enzymes
    • 4.1.1.2.1 Global Crispr And Cas Genes Kits And Enzymes Market, 2018 - 2030 (USD Million)
    • 4.1.1.2.2 Vector-Based Cas9
    • 4.1.1.2.2.1 Global Vector-Based Crispr And Cas Genes Market, 2018 - 2030 (USD Million)
    • 4.1.1.2.3 Dna-Free Cas9
    • 4.1.1.2.3.1 Global Dna-Free Crispr And Cas Genes Market, 2018 - 2030 (USD Million)
    • 4.1.1.3 Libraries
    • 4.1.1.3.1 Global Crispr And Cas Genes Libraries Market, 2018 - 2030 (USD Million)
    • 4.1.1.4 Design Tools
    • 4.1.1.4.1 Global Crispr And Cas Genes Design Tool Market, 2018 - 2030 (USD Million)
    • 4.1.1.5 Antibodies
    • 4.1.1.5.1 Global Crispr And Cas Genes Antibodies Market, 2018 - 2030 (USD Million)
    • 4.1.1.6 Others
    • 4.1.1.6.1 Global Crispr And Cas Genes Market For Others, 2018 - 2030 (USD Million)
  • 4.1.2 By Service
    • 4.1.2.1 Global Crispr And Cas Genes Service Market, 2018 - 2030 (USD Million)
    • 4.1.2.2 Cell Line Engineering
    • 4.1.2.2.1 Global Cell Engineering Services Market, 2018 - 2030 (USD Million)
    • 4.1.2.3 gRNA Design
    • 4.1.2.3.1 Global gRNA Design Market, 2018 - 2030 (USD Million)
    • 4.1.2.4 Microbial Gene Editing
    • 4.1.2.4.1 Global Microbial Gene Editing Market, 2018 - 2030 (USD Million)
    • 4.1.2.5 Dna Synthesis
    • 4.1.2.5.1 Global Dna Synthesis Market, 2018 - 2030 (USD Million)

Chapter 5 Application Business Analysis

• 5.1 Crispr And Cas Genes Market: Application Movement Analysis
  • 5.1.1 Biomedical
    • 5.1.1.1 Global Crispr And Cas Genes Market For Biomedical, 2018 - 2030 (USD Million)
    • 5.1.1.2 Genome Engineering
    • 5.1.1.2.1 Global Crispr And Cas Genes Market For Genome Engineering, 2018 - 2030 (USD Million)
    • 5.1.1.3 Disease Model Studies
    • 5.1.1.3.1 Global Crispr And Cas Genes Market For Disease Model Studies, 2018 - 2030 (USD Million)
    • 5.1.1.4 Functional Genomics
    • 5.1.1.4.1 Global Crispr And Cas Genes Market For Functional Genomics, 2018 - 2030 (USD Million)
    • 5.1.1.5 Epigenetics
    • 5.1.1.5.1 Global Crispr And Cas Genes Market For Epigenetics, 2018 - 2030 (USD Million)
    • 5.1.1.6 Others
    • 5.1.1.6.1 Global Crispr And Cas Genes Market For Others, 2018 - 2030 (USD Million)
  • 5.1.2 Agriculture
    • 5.1.2.1 Global Crispr And Cas Genes Market For Agriculture, 2018 - 2030 (USD Million)

Chapter 6 End-Use Business Analysis

• 6.1 Crispr And Cas Genes Market: End-Use Movement Analysis
  • 6.1.1 Biotechnology & Pharmaceutical Companies
    • 6.1.1.1 Global Crispr And Cas Genes Market For Biotechnology & Pharmaceutical Companies, 2018 - 2030 (USD Million)
  • 6.1.2 Academics & Government Research Institutes
    • 6.1.2.1 Global Crispr And Cas Genes Market For Academics & Government Research Institutes, 2018 - 2030 (USD Million)
  • 6.1.3 Contract Research Organizations (Cros)
    • 6.1.3.1 Global Crispr And Cas Genes Market For Contract Research Organizations (Cros), 2018 - 2030 (USD Million)

Chapter 7 Market Categorization: Regional Estimates & Trend Analysis by Product, Application & End-use

• 7.1 Regional Market Snapshot
• 7.2 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 7.2.1 North America
  • 7.2.2 Europe
  • 7.2.3 Asia Pacific
  • 7.2.4 Latin America
  • 7.2.5 Middle East And Africa
• 7.3 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
• 7.4 North America
  • 7.4.1 North America CRISPR And Cas Genes Market Estimates And Forecast, 2018-2030, (USD Billion)
  • 7.4.2 U.S.
    • 7.4.2.1 U.S. CRISPR & Cas Gene Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.4.3 Canada
    • 7.4.3.1 Canada CRISPR & Cas Genes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
• 7.5 Europe
  • 7.5.1 Europe CRISPR And Cas Genes Market Estimates And Forecast, 2018-2030, (USD Billion)
  • 7.5.2 Germany
    • 7.5.2.1 Germany CRISPR & Cas Gene Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.5.3 U.K.
    • 7.5.3.1 U.K. CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.5.4 France
    • 7.5.4.1 France CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.5.5 Italy
    • 7.5.5.1 Italy CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.5.6 Spain
    • 7.5.6.1 Spain CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.6 Asia Pacific
  • 7.6.1 Asia Pacific CRISPR And Cas Genes Market Estimates And Forecast, 2018-2030, (USD Billion)
  • 7.6.2 Japan
    • 7.6.2.1 Japan CRISPR & Cas Genes Market Estimates And Forecasts, 2018 - 2030 (USD Billion)
  • 7.6.3 China
    • 7.6.3.1 China CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6.4 South Korea
    • 7.6.4.1 South Korea CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6.5 India
    • 7.6.5.1 India CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.7 Latin America
  • 7.7.1 Latin America CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7.2 Brazil
    • 7.7.2.1 Brazil CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.7.3 Mexico
    • 7.7.3.1 Mexico CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 7.8 Middle East & Africa (Mea)
  • 7.8.1 MEA CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8.2 South Africa
    • 7.8.2.1 South Africa CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.8.3 Saudi Arabia
    • 7.8.3.1 Saudi Arabia CRISPR And Cas Genes Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

• 8.1 Top CRISPR Innovators and Their Research Focus
• 8.2 Strategy Framework
• 8.3 Market Participant Categorization
• 8.4 Company Profiles
  • 8.4.1 CARIBOU BIOSCIENCES
    • 8.4.1.1 Company Overview
    • 8.4.1.2 Financial Performance
    • 8.4.1.3 Product Benchmarking
    • 8.4.1.4 Strategic Initiatives
  • 8.4.2 ASTRAZENECA
    • 8.4.2.1 Company Overview
    • 8.4.2.2 Financial Performance
    • 8.4.2.3 Product Benchmarking
    • 8.4.2.4 Strategic Initiatives
  • 8.4.3 INTELLIA THERAPEUTICS, INC.
    • 8.4.3.1 Company Overview
    • 8.4.3.2 Financial Performance
    • 8.4.3.3 Product Benchmarking
    • 8.4.3.4 Strategic Initiatives
  • 8.4.4 ADDGENE
    • 8.4.4.1 Company Overview
    • 8.4.4.2 Financial Performance
    • 8.4.4.3 Product Benchmarking
  • 8.4.5 CRISPR THERAPEUTICS
    • 8.4.5.1 Company Overview
    • 8.4.5.2 Financial Performance
    • 8.4.5.3 Product Benchmarking
    • 8.4.5.4 Strategic Initiatives
  • 8.4.6 NEW ENGLAND BIOLABS
    • 8.4.6.1 Company Overview
    • 8.4.6.2 Financial Performance
    • 8.4.6.3 Product Benchmarking
    • 8.4.6.4 Strategic Initiatives
  • 8.4.7 THERMO FISHER SCIENTIFIC, INC.
    • 8.4.7.1 Company Overview
    • 8.4.7.2 Financial Performance
    • 8.4.7.3 Product Benchmarking
    • 8.4.7.4 Strategic Initiatives
  • 8.4.8 SYNTHEGO
    • 8.4.8.1 Company Overview
    • 8.4.8.2 Financial Performance
    • 8.4.8.3 Product Benchmarking
    • 8.4.8.4 Strategic Initiatives
  • 8.4.9 MAMMOTH BIOSCIENCES
    • 8.4.9.1 Company Overview
    • 8.4.9.2 Financial Performance
    • 8.4.9.3 Product Benchmarking
    • 8.4.9.4 Strategic Initiatives
  • 8.4.10 INSCRIPTA, INC.
    • 8.4.10.1 Company Overview
    • 8.4.10.2 Financial Performance
    • 8.4.10.3 Product Benchmarking
    • 8.4.10.4 Strategic Initiatives
  • 8.4.11 CIBUS
    • 8.4.11.1 Company Overview
    • 8.4.11.2 Financial Performance
    • 8.4.11.3 Product Benchmarking
    • 8.4.11.4 Strategic Initiatives
  • 8.4.12 BEAM THERAPEUTICS
    • 8.4.12.1 Company Overview
    • 8.4.12.2 Financial Performance
    • 8.4.12.3 Product Benchmarking
    • 8.4.12.4 Strategic Initiatives
  • 8.4.13 PLANTEDIT
    • 8.4.13.1 Company Overview
    • 8.4.13.2 Product Benchmarking
  • 8.4.14 VERTEX PHARMACEUTICALS INCORPORATED
    • 8.4.14.1 Company Overview
    • 8.4.14.2 Financial Performance
    • 8.4.14.3 Product Benchmarking
    • 8.4.14.4 Strategic Initiatives
  • 8.4.15 GENSCRIPT
    • 8.4.15.1 Company Overview
    • 8.4.15.2 Financial Performance
    • 8.4.15.3 Product Benchmarking
    • 8.4.15.4 Strategic Initiatives
  • 8.4.16 INTEGRATED DNA TECHNOLOGIES
    • 8.4.16.1 Company Overview
    • 8.4.16.2 Financial Performance
    • 8.4.16.3 Product Benchmarking
    • 8.4.16.4 Strategic Initiatives
  • 8.4.17 LONZA
    • 8.4.17.1 Company Overview
    • 8.4.17.2 Financial Performance
    • 8.4.17.3 Product Benchmarking
    • 8.4.17.4 Strategic Initiatives
  • 8.4.18 MERCK
    • 8.4.18.1 Company Overview
    • 8.4.18.2 Financial Performance
    • 8.4.18.3 Product Benchmarking
    • 8.4.18.4 Strategic Initiatives
  • 8.4.19 HERA BIOLABS
    • 8.4.19.1 Company Overview
    • 8.4.19.2 Product Benchmarking
    • 8.4.19.3 Strategic Initiatives
  • 8.4.20 ORIGENE TECHNOLOGIES, INC.
    • 8.4.20.1 Company Overview
    • 8.4.20.2 Financial Performance
    • 8.4.20.3 Product Benchmarking
  • 8.4.21 RECOMBINETICS, INC.
    • 8.4.21.1 Company Overview
    • 8.4.21.2 Financial Performance
    • 8.4.21.3 Product Benchmarking
    • 8.4.21.4 Strategic Initiative